Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:CTNM NASDAQ:GPCR NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$14.35+1.5%$12.30$5.31▼$17.43$1.06B1.713.51 million shs4.16 million shsCTNMContineum Therapeutics$10.05+0.4%$5.88$3.35▼$20.30$280.70M1.04254,713 shs212,446 shsGPCRStructure Therapeutics$19.14+0.7%$19.06$13.22▼$45.37$1.09B-1.89889,402 shs429,985 shsSTOKStoke Therapeutics$19.77+2.4%$13.93$5.35▼$19.97$1.06B1.15918,418 shs684,000 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+1.07%+4.59%+18.03%+15.71%+129.17%CTNMContineum Therapeutics+2.14%+12.85%+81.67%+180.39%-49.62%GPCRStructure Therapeutics+0.96%+2.32%+4.00%-15.25%-53.74%STOKStoke Therapeutics-0.36%-0.10%+50.66%+98.36%+39.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix2.7079 of 5 stars3.41.00.00.03.80.01.9CTNMContineum Therapeutics3.1744 of 5 stars3.65.00.00.02.70.80.6GPCRStructure Therapeutics2.8687 of 5 stars3.53.00.00.02.91.70.6STOKStoke Therapeutics4.4765 of 5 stars4.61.00.04.82.10.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.86Moderate Buy$17.3320.79% UpsideCTNMContineum Therapeutics 3.17Buy$22.75126.37% UpsideGPCRStructure Therapeutics 3.00Buy$75.71295.58% UpsideSTOKStoke Therapeutics 3.22Buy$25.5729.34% UpsideCurrent Analyst Ratings BreakdownLatest CTNM, GPCR, STOK, and CRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025STOKStoke TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$28.008/18/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $21.008/13/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.008/13/2025STOKStoke TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $22.008/8/2025CRMDCorMedixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $17.008/7/2025GPCRStructure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.008/7/2025GPCRStructure TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$92.00 ➝ $90.008/7/2025GPCRStructure TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$89.00 ➝ $87.007/18/2025STOKStoke TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.007/1/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.006/30/2025CRMDCorMedixD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M24.64N/AN/A$2.96 per share4.85CTNMContineum Therapeutics$50M5.64N/AN/A$6.11 per share1.64GPCRStructure TherapeuticsN/AN/AN/AN/A$13.40 per shareN/ASTOKStoke Therapeutics$36.56M29.63N/AN/A$6.11 per share3.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$17.93M$0.7519.1315.27N/A42.11%42.73%34.19%10/29/2025 (Estimated)CTNMContineum Therapeutics-$42.26M-$2.20N/AN/AN/AN/A-29.75%-28.08%11/5/2025 (Estimated)GPCRStructure Therapeutics-$122.53M-$1.05N/AN/AN/AN/A-21.31%-20.34%11/12/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.8523.26N/AN/A26.25%18.32%15.48%11/4/2025 (Estimated)Latest CTNM, GPCR, STOK, and CRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025STOKStoke Therapeutics-$0.57-$0.40+$0.17-$0.40$31.51 million$13.82 million8/7/2025Q2 2025CRMDCorMedix$0.20$0.28+$0.08$0.28$29.88 million$39.74 million8/6/2025Q2 2025GPCRStructure Therapeutics-$0.28-$0.36-$0.08-$0.36N/AN/A8/5/2025Q2 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/ACTNMContineum TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A7.827.52CTNMContineum TherapeuticsN/A24.5124.51GPCRStructure TherapeuticsN/A20.4820.48STOKStoke TherapeuticsN/A6.986.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%CTNMContineum TherapeuticsN/AGPCRStructure Therapeutics91.78%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCRMDCorMedix5.30%CTNMContineum Therapeutics11.30%GPCRStructure Therapeutics5.60%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3074.65 million70.69 millionOptionableCTNMContineum Therapeutics3128.04 million24.87 millionN/AGPCRStructure Therapeutics13657.60 million54.37 millionOptionableSTOKStoke Therapeutics10054.80 million49.59 millionOptionableCTNM, GPCR, STOK, and CRMD HeadlinesRecent News About These CompaniesStoke Therapeutics to Present at Upcoming Investor Conferences in September 2025August 28 at 5:01 PM | businesswire.comStoke Therapeutics: Vulnerable To Profit TakingAugust 27 at 10:06 AM | seekingalpha.comStoke Therapeutics Beats Shareholder Challenge to Board BylawAugust 26 at 3:41 PM | news.bloomberglaw.comN396,000 Shares in Stoke Therapeutics, Inc. $STOK Purchased by Erste Asset Management GmbHAugust 24, 2025 | marketbeat.com13,780 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Fox Run Management L.L.C.August 24, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Hits New 1-Year High - Still a Buy?August 22, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Buy" by BrokeragesAugust 20, 2025 | marketbeat.comEquities Analysts Issue Forecasts for STOK FY2025 EarningsAugust 19, 2025 | marketbeat.comStoke Therapeutics price target lowered to $28 from $29 at BTIGAugust 18, 2025 | msn.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK)August 18, 2025 | prnewswire.comFY2025 Earnings Estimate for STOK Issued By Chardan CapitalAugust 18, 2025 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 13,712 SharesAugust 17, 2025 | marketbeat.comCantor Fitzgerald Brokers Lift Earnings Estimates for STOKAugust 17, 2025 | marketbeat.comResearch Analysts Offer Predictions for STOK Q3 EarningsAugust 17, 2025 | marketbeat.comLeerink Partnrs Has Positive Forecast for STOK Q3 EarningsAugust 17, 2025 | marketbeat.comQ3 EPS Estimate for Stoke Therapeutics Increased by AnalystAugust 17, 2025 | marketbeat.comLeerink Partnrs Has Optimistic Outlook of STOK Q3 EarningsAugust 17, 2025 | americanbankingnews.comHC Wainwright Issues Optimistic Forecast for STOK EarningsAugust 17, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Forecast for STOK FY2029 Earnings?August 16, 2025 | marketbeat.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 13,712 Shares of StockAugust 16, 2025 | insidertrades.comStoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Chardan CapitalAugust 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTNM, GPCR, STOK, and CRMD Company DescriptionsCorMedix NASDAQ:CRMD$14.35 +0.21 (+1.49%) Closing price 04:00 PM EasternExtended Trading$14.32 -0.03 (-0.21%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Contineum Therapeutics NASDAQ:CTNM$10.05 +0.04 (+0.40%) Closing price 04:00 PM EasternExtended Trading$10.32 +0.26 (+2.64%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Structure Therapeutics NASDAQ:GPCR$19.14 +0.14 (+0.74%) Closing price 04:00 PM EasternExtended Trading$18.94 -0.20 (-1.02%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Stoke Therapeutics NASDAQ:STOK$19.77 +0.47 (+2.44%) Closing price 04:00 PM EasternExtended Trading$19.85 +0.08 (+0.40%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big Chevron Stock Outlook: Dividend Growth Meets Inflation As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access